ane portfolio, delivering growth in a soft market. Key recent highlights include the U.S. FDA approval of RestylaneContour™ for the correction of temple hollowing and the global ‘Wake Up To Restylane’ campaign, positioning Restylane as an everyday natural beauty ally. Sculptra maintains its double-digit growth momentum in both geographies. In addition to strengthening Sculptra’s position in regenerative aesthetics and expanding into body indications in Europe, Galderma launched its ‘We Are All Sculptra’ program, following nine new patients over two years to highlight its real-life regenerative impact.

Dermatological Skincare

Dermatological Skincare net sales for the first quarter were 441 million USD, with year-on-year growth of 17.0% at constant currency.

Both Dermatological Skincare flagship brands, Cetaphil and Alastin, maintained strong growth momentum, also benefitting from a lower comparable base for the period. Gr
=*=*=*=*=*=
当前为第6/27页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页